GlassScriptPhysician profile
Victor Boyd Deaton
NPI 1205514338
$12,607.54
in general payments reported to CMS, 2019-2025
42 companies · $6,577 in 2025
The $6,577 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $19.74 · 2024: $6,011 · 2025: $6,577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $57.27 · Education: $10.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,539.52 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $57.27 |
| Education | $10.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,620.03 | 2024-2025 | |
| Ucb, INC. | $1,314.29 | 2024-2025 | Rystiggo, Briviact, Nayzilam |
| Ani Pharmaceuticals, INC. | $867.41 | 2024-2025 | Purified Cortrophin Gel |
| Neurocrine Biosciences, INC. | $683.93 | 2024-2025 | Ingrezza |
| Sk Life Science, INC. | $675.97 | 2024-2025 | Xcopri |
| Biogen, INC. | $658.02 | 2024-2025 | Vumerity, Skyclarys |
| Novartis Pharmaceuticals Corporation | $629.46 | 2024-2025 | |
| Lundbeck LLC | $585.97 | 2024-2025 | Vyepti, Rexulti |
| Emd Serono, INC. | $583.07 | 2024-2025 | |
| Pfizer INC. | $540.34 | 2023-2025 | |
| Mdd US Operations, LLC | $465.40 | 2024-2025 | Apokyn, Gocovri, Myobloc |
| Alexion Pharmaceuticals, INC. | $362.15 | 2024-2025 | Ultomiris |
| Argenx US, INC. | $341.89 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Tg Therapeutics, INC. | $338.37 | 2024-2025 | |
| Acadia Pharmaceuticals INC | $275.39 | 2024-2025 | Nuplazid |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cycle Pharmaceuticals INC | $235.37 | 2024-2025 | Tascenso Odt, Bafiertam |
| Lilly USA, LLC | $213.01 | 2024-2025 | Amyvid, Emgality, Kisunla |
| Celgene Corporation | $195.55 | 2024-2025 | Zeposia |
| Csl Behring | $191.39 | 2024-2025 | Hizentra, Privigen |
| Catalyst Pharmaceuticals, INC. | $189.75 | 2024-2025 | |
| Axsome Therapeutics, INC. | $170.64 | 2025 | Symbravo |
| Teva Pharmaceuticals USA, INC. | $138.28 | 2024-2025 | Austedo Xr, Austedo Xr |
| Eisai INC. | $137.16 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $132.34 | 2024-2025 | Rexulti |
| Azurity Pharmaceuticals, INC. | $117.67 | 2024-2025 | Horizant |
| Amneal Pharmaceuticals LLC | $111.70 | 2024-2025 | Crexont |
| Genentech USA, INC. | $108.65 | 2024-2025 | Ocrevus Zunovo |
| Alnylam Pharmaceuticals INC. | $86.20 | 2024-2025 | Onpattro |
| Vanda Pharmaceuticals INC. | $80.57 | 2024-2025 | Ponvory |
| Sumitomo Pharma America, INC. | $77.19 | 2024 | Aptiom |
| Neurelis, INC. | $75.96 | 2024-2025 | Valtoco |
| Grifols USA, LLC | $67.21 | 2025 | Gamunex-C |
| Scilex Pharmaceuticals INC. | $58.12 | 2024-2025 | |
| Kyowa Kirin, INC. | $54.59 | 2024 | Nourianz |
| Harmony Biosciences LLC | $39.89 | 2024 | |
| Acorda Therapeutics, INC | $35.80 | 2024 | Inbrija |
| Tanabe Pharma America, INC. | $34.49 | 2024 | |
| Octapharma USA, INC. | $29.37 | 2024 | Cutaquig, Panzyga |
| Mallinckrodt Hospital Products INC. | $28.26 | 2025 | Acthar |
| Impel Pharmaceuticals LLC | $24.04 | 2025 | Trudhesa |
| Banner Life Sciences, LLC | $18.12 | 2024 | |
| Amgen INC. | $14.53 | 2025 | Uplizna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Deaton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.